Potential SARS-CoV-2 main protease inhibitors
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Graphical abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, J. D., Higgins, D. G., & Gibson, T. J. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4673 · Cited by 64,617
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2223-y · Cited by 4,358
Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020) · Science · doi:10.1126/science.abb3405 · Cited by 2,895
Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic
(2020) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-200220-0772 · Cited by 1,537
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Dong, L., Hu, S., & Gao, J. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.01012 · Cited by 1,390
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants
Tahir ul Qamar, M., Alqahtani, S. M., Alamri, M. A., & Chen, L.-L. (2020) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2020.03.009 · Cited by 1,032
Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance
Dickey, S. W., Cheung, G. Y. C., & Otto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.23 · Cited by 799
Morse, J. S., Lalonde, T., Xu, S., & Liu, W. R. (2020) · ChemBioChem · doi:10.1002/cbic.202000047 · Cited by 776
Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases
Yang, H., Xie, W., Xue, X., Yang, K., Ma, J., Liang, W., Zhao, Q., Zhou, Z., Pei, D., Ziebuhr, J., et al. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030324 · Cited by 727
Seah, I., & Agrawal, R. (2020) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2020.1738501 · Cited by 698
Xu, J., Zhao, S., Teng, T., Abdalla, A. E., Zhu, W., Xie, L., Wang, Y., & Guo, X. (2020) · Viruses · doi:10.3390/v12020244 · Cited by 683
From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
Hilgenfeld, R. (2014) · The FEBS Journal · doi:10.1111/febs.12936 · Cited by 660
Ashour, H. M., Elkhatib, W. F., Rahman, M. M., & Elshabrawy, H. A. (2020) · Pathogens · doi:10.3390/pathogens9030186 · Cited by 607
Protease inhibitors targeting coronavirus and filovirus entry
Zhou, Y., Vedantham, P., Lu, K., Agudelo, J., Carrion, R., Nunneley, J. W., Barnard, D., Pöhlmann, S., McKerrow, J. H., Renslo, A. R., et al. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.01.011 · Cited by 583
Zhang, L., Lin, D., Kusov, Y., Nian, Y., Ma, Q., Wang, J., von Brunn, A., Leyssen, P., Lanko, K., Neyts, J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01828 · Cited by 568
Ton, A., Gentile, F., Hsing, M., Ban, F., & Cherkasov, A. (2020) · Molecular Informatics · doi:10.1002/minf.202000028 · Cited by 517
Wang, J. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00179 · Cited by 498
Xue, X., Yu, H., Yang, H., Xue, F., Wu, Z., Shen, W., Li, J., Zhou, Z., Ding, Y., Zhao, Q., et al. (2008) · Journal of Virology · doi:10.1128/jvi.02114-07 · Cited by 473
Drug–target residence time: critical information for lead optimization
Lu, H., & Tonge, P. J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.176 · Cited by 432
Muralidharan, N., Sakthivel, R., Velmurugan, D., & Gromiha, M. M. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1752802 · Cited by 415
Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Kandeel, M., & Al-Nazawi, M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117627 · Cited by 412
Das, S., Sarmah, S., Lyndem, S., & Singha Roy, A. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1763201 · Cited by 380
Joshi, R. S., Jagdale, S. S., Bansode, S. B., Shankar, S. S., Tellis, M. B., Pandya, V. K., Chugh, A., Giri, A. P., & Kulkarni, M. J. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1760137 · Cited by 354
Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors
Bhardwaj, V. K., Singh, R., Sharma, J., Rajendran, V., Purohit, R., & Kumar, S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1766572 · Cited by 347
Gentile, D., Patamia, V., Scala, A., Sciortino, M. T., Piperno, A., & Rescifina, A. (2020) · Marine Drugs · doi:10.3390/md18040225 · Cited by 319
Ghosh, R., Chakraborty, A., Biswas, A., & Chowdhuri, S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1779818 · Cited by 301
Drug–Target Kinetics in Drug Discovery
Tonge, P. J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00185 · Cited by 287
Mirza, M. U., & Froeyen, M. (2020) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2020.04.008 · Cited by 284
Kil, J., Lobarinas, E., Spankovich, C., Griffiths, S. K., Antonelli, P. J., Lynch, E. D., & Le Prell, C. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31791-9 · Cited by 265
Khaerunnisa, S., Kurniawan, H., Awaluddin, R., Suhartati, S., & Soetjipto, S. (2020) · doi:10.20944/preprints202003.0226.v1 · Cited by 256
Mittal, L., Kumari, A., Srivastava, M., Singh, M., & Asthana, S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1768151 · Cited by 207
Adem, S., Eyupoglu, V., Sarfraz, I., Rasul, A., & Ali, M. (2020) · Preprints.org · doi:10.20944/preprints202003.0333.v1 · Cited by 198
Grum-Tokars, V., Ratia, K., Begaye, A., Baker, S. C., & Mesecar, A. D. (2008) · Virus Research · doi:10.1016/j.virusres.2007.02.015 · Cited by 190
Wang, F., Chen, C., Tan, W., Yang, K., & Yang, H. (2016) · Scientific Reports · doi:10.1038/srep22677 · Cited by 189
Macchiagodena, M., Pagliai, M., & Procacci, P. (2020) · Chemical Physics Letters · doi:10.1016/j.cplett.2020.137489 · Cited by 172
Lee, T.-W., Cherney, M. M., Huitema, C., Liu, J., James, K. E., Powers, J. C., Eltis, L. D., & James, M. N. G. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.09.004 · Cited by 170
Shamsi, A., Mohammad, T., Anwar, S., AlAjmi, M. F., Hussain, A., Rehman, M. T., Islam, A., & Hassan, M. I. (2020) · Bioscience Reports · doi:10.1042/bsr20201256 · Cited by 167
Gimeno, A., Mestres-Truyol, J., Ojeda-Montes, M. J., Macip, G., Saldivar-Espinoza, B., Cereto-Massagué, A., Pujadas, G., & Garcia-Vallvé, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113793 · Cited by 165
Computational Determination of Potential Inhibitors of SARS-CoV‑2 Main Protease
Ngô, S. T., Pham, N. Q. A., Le, L., Pham, D.-H., & Vu, V. V. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00491 · Cited by 163
Structure-based drug designing and immunoinformatics approach for SARS-CoV-2
Panda, P. K., Murugan, N. A., Patel, P., Verma, S. K., Luo, W., Rubahn, H., Mishra, Y. K., Suar, M., & Ahuja, R. (2020) · Science Advances · doi:10.1126/sciadv.abb8097 · Cited by 159
Gurung, A. B., Ali, M. A., Lee, J., Farah, M. A., & Al‐Anazi, K. M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117831 · Cited by 157
Kumar, V., Dhanjal, J. K., Kaul, S. C., Wadhwa, R., & Sundar, D. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1772108 · Cited by 149
AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2
Tang, B., He, F., Liu, D., He, F., Wu, T., Fang, M., Niu, Z., Wu, Z., & Xu, D. (2022) · Biomolecules · doi:10.3390/biom12060746 · Cited by 144
Lee, C., Kuo, C., Ko, T., Hsu, M.-F., Tsui, Y.-C., Chang, S., Yang, S., Chen, S.-J., Chen, H., Hsu, M., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807947200 · Cited by 143
Alamri, M. A., Qamar, M. T. U., Mirza, M. U., Bhadane, R. N., Alqahtani, S. M., Muneer, I., Froeyen, M., & Salo‐Ahen, O. M. H. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1782768 · Cited by 138
Owis, A. I., El-Hawary, M. S., Amir, D. E., Aly, O. M., Abdelmohsen, U. R., & Kamel, M. S. (2020) · RSC Advances · doi:10.1039/d0ra03582c · Cited by 130
From Target to Drug: Generative Modeling for the Multimodal Structure-Based Ligand Design
Skalic, M., Sabbadin, D., Sattarov, B., Sciabola, S., & De Fabritiis, G. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00634 · Cited by 125
Zhu, L., George, S., Schmidt, M. F., Al-Gharabli, S. I., Rademann, J., & Hilgenfeld, R. (2011) · Antiviral Research · doi:10.1016/j.antiviral.2011.08.001 · Cited by 119
Sharma, A., & Kaur, I. (2020) · Preprints.org · doi:10.20944/preprints202003.0455.v1 · Cited by 107
Strodel, B., Olubiyi, O. O., Olagunju, M. O., Keutmann, M., & Loschwitz, J. (2020) · Molecules · doi:10.3390/molecules25143193 · Cited by 102
Ghosh, A. K., Xi, K., Grum-Tokars, V. L., Xu, X., Ratia, K. M., Fu, W., Houser, K. V., Baker, S. C., Johnson, M. E., & Mesecar, A. D. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.08.031 · Cited by 102
Potential 2019-nCoV 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches
Zhavoronkov, A., Aladinskiy, V., Zhebrak, A., Zagribelnyy, B., Terentiev, V., Bezrukov, D. S., Polykovskiy, D., Shayakhmetov, R., Filimonov, A., Orekhov, P., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.11829102.v1 · Cited by 100
Kumar, V., Shin, J. S., Shie, J., Ku, K. B., Kim, C., Go, Y. Y., Huang, K.-F., Kim, M., & Liang, P. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.02.007 · Cited by 100
Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning ApproachesPreprint
Zhavoronkov, A. A., Aladinskiy, V., Zhebrak, A., Zagribelnyy, B. A., Terentiev, V. A., Bezrukov, D. S., Polykovskiy, D. A., Shayakhmetov, R., Filimonov, A., Orekhov, P. S., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.11829102 · Cited by 100
Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus
Liu, S., Zheng, Q., & Wang, Z. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa224 · Cited by 100
Interaction between RAAS inhibitors and ACE2 in the context of COVID-19
Mourad, J., & Levy, B. I. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0368-x · Cited by 98
Bouchentouf, S., & Noureddine, M. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12055716.v1 · Cited by 97
Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing
Masaki, C., Sharpley, A. L., Cooper, C. M., Godlewska, B. R., Singh, N., Vasudevan, S. R., Harmer, C. J., Churchill, G. C., Sharp, T., Rogers, R. D., et al. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4319-5 · Cited by 96
Structure of the Main Protease from a Global Infectious Human Coronavirus, HCoV-HKU1
Zhao, Q., Li, S., Xue, F., Zou, Y., Chen, C., Bartlam, M. G., & Rao, Z. (2008) · Journal of Virology · doi:10.1128/jvi.00298-08 · Cited by 95
Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors
Jiménez-Alberto, A., Ribas‐Aparicio, R. M., Aparicio‐Ozores, G., & Castelán-Vega, J. A. (2020) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2020.107325 · Cited by 90
Chang, A. T., Schiebel, J., Yu, W., Bommineni, G. R., Pan, P., Baxter, M. V., Khanna, A., Sotriffer, C., Kisker, C., & Tonge, P. J. (2013) · Biochemistry · doi:10.1021/bi400413c · Cited by 63
The SARS-like coronaviruses: the role of bats and evolutionary relationships with SARS coronavirus.
Balboni, A., Battilani, M., & Prosperi, S. (2012) · PubMed · doi:10.5281/zenodo.13493081 · Cited by 56
Ai, Y.-B., Yu, L.-L., Tan, X., Chai, X., & Liu, S. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00334 · Cited by 56
Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug RepositioningPreprint
Farag, A., Wang, P., Ahmed, M., & Sadek, H. A. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12003930.v1 · Cited by 56
Liu, Y., Chan, W. K. B., Wang, Z., Hur, J., Xie, J., Yu, H. J., & He, Y. O. (2020) · Preprints.org · doi:10.20944/preprints202003.0413.v1 · Cited by 38
Sharma, A. D., & Kaur, I. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2004.00217 · Cited by 37
Verma, D. K., Kapoor, S., Das, S., & Thakur, K. G. (2022) · Biomedicines · doi:10.3390/biomedicines11010085 · Cited by 32
Wang, F., Chen, C., Liu, X., Yang, K., Xu, X., & Yang, H. (2015) · Journal of Virology · doi:10.1128/jvi.02685-15 · Cited by 31
The crystal structure of main protease from mouse hepatitis virus A59 in complex with an inhibitor
Cui, W., Cui, S., Chen, C., Chen, X., Wang, Z., Yang, H., & Zhang, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.02.105 · Cited by 30
Pathak, Y., Mishra, A., Choudhir, G., Kumar, A., & Tripathi, V. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00228-0 · Cited by 27
In Silico Investigations on the Potential Inhibitors for COVID-19 ProteasePreprint
Srivastava, A. K., Kumar, A., Tiwari, G., Kumar, R., & Misra, N. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2003.10642 · Cited by 25
Leucoefdin a potential inhibitor against SARS CoV-2 M pro
Singh, A., & Mishra, A. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1777903 · Cited by 23
Rifampicin may be repurposed for COVID-19 treatment: Insights from an in-silico studyPreprint
Pathak, Y., Mishra, A., & Tripathi, V. (2020) · doi:10.21203/rs.3.rs-22546/v1 · Cited by 17
Patel, R. B., Vanzara, A., Patel, N., Vasava, A. M., Patil, S. P., & Rajput, K. S. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12523136 · Cited by 13
Metadata
- Authors
- Banerjee, R., Perera, L., & Tillekeratne, L. M. V.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 26
- Issue
- 3
- Pages
- 804-816
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W3113166651
- Cited by
- 183
- References
- 76
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.